Drawing for ACTAVIS PHARMA

USPTO serial 85830300

ACTAVIS PHARMA

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
SNAPP, TINA LOUISE
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with ACTAVIS PHARMA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Gabrielle S. Roth

GABRIELLE S ROTH SUGHRUE MION PLLC2100 PENNSYLVANIA AVE NWWASHINGTON, DC 20037-3213UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Chemicals used in industry and science, namely, active chemical ingredients for use in the manufacture of pharmaceuticals, chemical additives for use in the manufacture of pharmaceuticals; chemical preparations for scientific purposes; chemical preparations for use in industryACTIVE—
003Soaps, perfumery, essential oils, cosmetics, namely, cosmetic preparations for skin care, cosmetic preparations for body care, cosmetic preparations for bath and shower, cosmetic creams, lotions, and ointments and gels for skin care, cosmetic skin fresheners and toners, cosmetic preparations for the hair and scalp, and hair lotions; dentifrices, namely, anti-cavity dental rinses, mouth rinses and mouth washes; cosmetic preparations for the care of mouth and teeth; skin and hair care preparations not for medical useACTIVE—
005Pharmaceuticals, namely, preparations and substances for the prevention and treatment of alimentary tract and metabolic diseases and disorders, dermatological diseases and disorders, genito-urinary and sexual diseases and disorders, musculo-skeletal system diseases and disorders, nervous system diseases and disorders, respiratory system diseases and disorders, cardio-vascular diseases and disorders specifically excluding tissue plasminogen activators, sensory organ diseases and disorders, systemic hormonal pharmaceutical preparations and substances, pharmaceuticals, namely, anti-infectives, pharmaceutical preparations, namely, antineoplastic and immunomodulating agents, antiparasitic preparations and substances; contraceptives; hormone replacement therapy preparations; pharmaceutical preparations for the prevention of preterm birth or pregnancy; pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; pharmaceutical preparations for the treatment and prevention of osteoporosis; pharmaceutical preparations for the treatment and prevention of endometriosis; pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; iron chelating pharmaceutical preparations; fertility enhancing preparations, pharmaceutical preparations and substances for the treatment of premenstrual syndrome, post natal depression, fluctuating hormone levels, pharmaceutical preparations and substances for infertility disorders, pharmaceutical preparations and substances for in vitro fertilization (ivf); pharmaceutical preparations in the nature of medicated dental rinses, mouth rinses, mouthwashes, dental lozenges, dental tablets and medicated chewing gum; dental wax; pharmaceutical preparations in the nature of pregnancy test kits, ovulation test kits and in-vitro ovulation prediction test kits all for home use; pharmaceutical preparations in the nature of diagnostic test kits for home use for detecting urinary tract infections, for detecting menopause, for detecting vaginal pH balances and for detecting sexually-transmitted diseases; pharmaceutical preparations for skin care; all the foregoing specifically excluding tissue plasminogen activatorsACTIVE—
041Educational services, namely, conducting conferences, seminars, webinars, video case studies, classes and workshops in the fields of healthcare, women's health, pharmaceuticals and medicine, pharmaceutical research and developmentACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Apr 9, 2018MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Apr 9, 2018ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Sep 19, 2017EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Sep 18, 2017EX5GSOU EXTENSION 5 GRANTED—
Sep 5, 2017EXT5SOU EXTENSION 5 FILED—
Sep 5, 2017EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Mar 7, 2017EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Mar 3, 2017EX4GSOU EXTENSION 4 GRANTED—
Mar 3, 2017EXT4SOU EXTENSION 4 FILED—
Mar 3, 2017EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 22, 2017ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Sep 14, 2016EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Sep 13, 2016EX3GSOU EXTENSION 3 GRANTED—
Sep 6, 2016EXT3SOU EXTENSION 3 FILED—
Sep 6, 2016EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Mar 12, 2016EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Mar 11, 2016EX2GSOU EXTENSION 2 GRANTED—
Mar 10, 2016AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Feb 9, 2016EXT2SOU EXTENSION 2 FILED—
Feb 9, 2016EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Aug 26, 2015EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Aug 24, 2015EX1GSOU EXTENSION 1 GRANTED—
Aug 24, 2015EXT1SOU EXTENSION 1 FILED—
Aug 24, 2015EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Mar 3, 2015NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jan 20, 2015TMBNTTAB RELEASE CASE TO TRADEMARKS—
Jan 20, 2015OP.TOPPOSITION TERMINATED NO. 999999—
Jan 6, 2015OP.DOPPOSITION DISMISSED NO. 999999—
Jul 31, 2014OP.IOPPOSITION INSTITUTED NO. 999999—
Jul 18, 2014UNDNUNDELIVERABLE MAIL - NO ACTION TAKEN—
Feb 27, 2014ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Feb 4, 2014NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 4, 2014PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 15, 2014NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Dec 28, 2013PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Dec 27, 2013ALIEASSIGNED TO LIE—
Dec 3, 2013CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 3, 2013XAECEXAMINER'S AMENDMENT ENTERED—
Dec 3, 2013GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Dec 3, 2013GNEAEXAMINERS AMENDMENT E-MAILED—
Dec 3, 2013CNEAEXAMINERS AMENDMENT -WRITTEN—
Nov 24, 2013GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Nov 24, 2013GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Nov 24, 2013CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Nov 4, 2013TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 4, 2013CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 4, 2013TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 30, 2013ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 30, 2013REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
May 14, 2013GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 14, 2013GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 14, 2013CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 3, 2013DOCKASSIGNED TO EXAMINER—
Mar 20, 2013ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Jan 29, 2013NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 26, 2013NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance